Quick Answer
BridgeBio Oncology Therapeutics, Inc. reported Research And Development Expense of $121.20 million for the year ending 2025.
- BridgeBio Oncology Therapeutics, Inc. showed an increase of +65.8% in Research And Development Expense from 2024 to 2025.
- This data is from BridgeBio Oncology Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2024 to 2025 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Historical annual values: Fiscal year 2025: $121.20 million | Fiscal year 2024: $73.11 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: